Remona buys AGN 288: On average, analysts predict that Allergan will post $17.84 EPS for the current year.

During the same period in the prior year, the firm earned $3.42 EPS. Allergan (NYSE:AGN) last released its earnings results on Thursday, August 6th. Shares of Allergan ( NYSE:AGN ) traded down 3.97% during trading on Friday, hitting $279.03. 4,929,801 shares of the stock were exchanged. In other Allergan news, CEO Brent L. JPMorgan Chase & Co. began coverage on Allergan in a report on Monday, August 3rd.


Johnny:
During the same quarter in the prior year, the firm posted $3.42 earnings per share.

Marisela:
Developers of biosimilars have repeatedly said that the difference in price of biosimilars and their reference biologics should not be viewed as a difference in quality.

Lashawn:
Biosimilars cost less than reference drugs.

Carmelina:
This provides a promising opportunity to drugmakers to tap into.

Leslee:
The market is expected to reach $11 billion by 2020, according to reports.

Petra:
The drugmaker has eight other biosimilar candidates in its pipeline.

Rona:
Avastin biosimilar, ABP 215, if approved by the FDA, would be the first biosimilar drug by Amgen.

Risa:
Zarxio was finally launched in the U.S. earlier this month.

Rosena:
The biosimilar was developed by Novartis AG ADR ( NYSE:NVS ) and had to face a series of lawsuits by Amgen, which were primarily aimed at delaying its launch.

Emmie:
Patient Protection and Affordable Care Act of 2010, regulators are allowed to grant approval of biosimilar drugs after a detailed examination.

Allergan (NYSE:AGN)
//stockhand.net/us/?q=nyse%3Aagn&id=631547